摘要
目的:探讨艾迪注射液在进展期胃癌中的应用疗效及对美国东部肿瘤合作组(Eastern Cooperative Oncology Group,ECOG)评分、不良事件的影响。方法:选取2020年1月-2021年12月九江市第一人民医院收治的70例进展期胃癌患者作为研究对象,用随机数字表法将其分对照组和观察组,各35例,对照组接受奥沙利铂联合卡培他滨方案治疗,观察组接受艾迪注射液联合奥沙利铂、卡培他滨治疗,比较两组患者治疗效果、ECOG评分、肿瘤标志物水平、细胞免疫指标、生活质量、不良反应发生率。结果:观察组治疗总有效率91.43%高于对照组的68.57%,差异有统计学意义(P<0.05);治疗前,两组间ECOG评分、QOL评分差异均无统计学意义(P>0.05),治疗后,观察组ECOG评分低于对照组、QOL评分高于对照组,差异均有统计学意义(P<0.05);治疗前,两组间肿瘤标志物水平差异均无统计学意义(P>0.05),治疗后,观察组糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、糖类抗原72-4(CA72-4)均低于对照组,差异均有统计学意义(P<0.05);治疗前,两组间细胞免疫指标差异均无统计学意义(P>0.05),治疗后,观察组^(+)CD8低于对照组,CD4^(+)、CD3^(+)均高于对照组,差异均有统计学意义(P<0.05);治疗前,两组间VEGF、MMP-9差异均无统计学意义(P>0.05),治疗后,观察组VEGF、MMP-9均低于对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率20.00%低于对照组的22.86%,但差异无统计学意义(P>0.05)。结论:临床治疗进展期胃癌病变,可在奥沙利铂联合卡培他滨基础上,再给予艾迪注射液,能进一步提升机体免疫功能,改善肿瘤标志物水平,进而提升疗效,并改善其生活质量。
Objective:To investigate the efficacy of Aidi Injection in advanced gastric cancer and its influence on ECOG score and adverse events.Method:A total of 70 patients with advanced gastric cancer admitted to Jiujiang NO.1 People's Hospital from January 2020 to December 2021 were selected as the research objects,and they were randomly divided into the control group and the observation group,with 35 patients in each group.The control group received Oxaliplatin combined with Capecitabine regimen,and the observation group received Aidi Injection combined with Oxaliplatin and Capecitabine.The therapeutic effect,ECOG score,tumor marker level,cellular immune indicators,quality of life,incidence rate of adverse reactions between the two groups of patients were compared.Result:The total effective rate in the observation group was 91.43%,higher than 68.57%in the control group,with a statistically significant difference(P<0.05).Before treatment,there were no statistically significant differences in ECOG score and QOL score between the two groups(P>0.05);after treatment,the ECOG score of the observation group was lower than that of the control group,and the QOL score was higher than that of the control group,with statistical significance(P<0.05).Before treatment,there were no statistically significant differences in tumor marker levels between the two groups(P>0.05),after treatment,the levels of carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA)and carbohydrate antigen 72-4(CA72-4)in the observation group were lower than those in the control group,the differences were all statistically significant(P<0.05).Before treatment,there were no statistically significant differences in cellular immune indicators between the two groups(P>0.05);after treatment,CD8^(+)in the observation group was lower than that in the control group,while CD4^(+)and CD3^(+)were higher than those in the control group,with statistical significance(P<0.05).Before treatment,there were no statistically significant differences in VEGF and MMP-9 between the two groups(P>0.05);after treatment,the VEGF and MMP-9 levels in the observation group were lower than those in the control group,with statistical significance(P<0.05);the incidence of adverse reactions in the observation group was 20.00%,which was lower than 22.86%in the control group,but the difference was not statistically significant(P>0.05).Conclusion:On the basis of Oxaliplatin combined with Capecitabine,Aidi Injection can further enhance the immune function of the body,improve the levels of tumor markers,and then improve the efficacy and quality of life of patients with advanced gastric cancer.
作者
罗素梅
熊超
曾灵芝
杨敏捷
LUO Sumei;XIONG Chao;ZENG Lingzhi;YANG Minjie(Jiujiang NO.1 People's Hospital,Jiangxi Province,Jiujiang 332000,China)
出处
《中国医学创新》
CAS
2023年第18期19-23,共5页
Medical Innovation of China
